Mice treated with the small-molecule compound improved muscle strength, increased motor neuron survival and boosted production of a motor-neuron support molecule called VEGF
posted on March 4, 2013 - 5:00am
Mice with a disorder mimicking human spinal-bulbar muscular atrophy (SBMA, or Kennedy disease) that were treated with an experimental therapy called arimoclomol showed improved nerve-cell survival, increased body weight, and better muscle strength and function than mice that didn't receive the treatment.
After a two-year review, the FDA approves reopening a clinical trial of the experimental compound arimoclomol.
posted on December 8, 2009 - 5:45pm
A clinical trial of an experimental drug for ALS -- halted almost two years ago due to safety concerns –- has been given the green light to continue with a revised protocol, says CytRx Corp. of Los Angeles, the drug’s manufacturer.
The U.S. Food and Drug Administration placed a hold on the phase 2b trial of arimoclomol in January 2008, saying it wanted to see more toxicity data from previously...